co.don AG establishes Scientific Advisory Board

Berlin, 10 May 2016 - As part of its ongoing market penetration in Germany and in preparation for European market expansion, co.don AG has set up a Scientific Advisory Board, which met for the first time in late April in Berlin.

The board will be chaired by Professor Dr. med. Philipp Niemeyer, senior consultant for cartilage surgery at the Orthopaedic and Accident Surgery Clinic at the University Clinic Freiburg, and specialist for orthopaedics and traumatology at the Orthopaedic Surgery Clinic in Munich.

The other board members are Professor Dr. med. Norbert Klusen, professor for International Health Policy and Health Systems at Hanover University, Professor Dr. med. Stefan Marlovits, specialist for traumatology and sports traumatology, head of the Centre for Cartilage Regeneration and Orthobiology at Vienna Medical Hospital, PD Dr. med. Hannjörg Koch, specialist for orthopaedic surgery at the Centre for Insurance Medicine, Swiss Casualty Insurance (SUVA) Lucerne, Dr. Barbara Wondrasch, physiotherapist in Vienna and Dr. med. Gregor Möckel, specialist for orthopaedics and traumatology, senior consultant for arthroscopic and reconstructive joint surgery, Asklepios Klinik Birkenwerder. co.don AG is represented by its CEO, Dirk Hessel, and Kristin Schindler, Vice President Marketing & Sales.

Among the objectives of the Scientific Advisory Board – in addition to providing scientific advice on strategic matters – are to answer medical questions in the field of regenerative cartilage therapy and to optimise existing products in terms of user-friendliness.

To prepare for the European launch of the product the intention is to establish contacts to medical and academic opinion leaders in selected EU countries.  The board will also carry out systematic analyses and interpretations of scientific trials.

Dirk Hessel, CEO of co.don AG: "By setting up this Scientific Advisory Board and publicising the results of its work we are underlining the good results that we have obtained with our method of autologous chondrocyte therapy and are also strengthening our competence in this area. This kind of scientific support is indispensable for continuing to make our methods a firm fixture of everyday clinical practice. I am delighted that such leading experts have agreed to join our Scientific Advisory Board, and on behalf of co.don AG I thank all the members of the Scientific Advisory Board for their support. We are convinced that we have implemented a very promising idea for the continued success of the co.don method in Germany and for opening up the European market."

About co.don® AG: Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects. co.don condrosphere® is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). co.don condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere® has been used for more than 10 years in over 120 clinics to treat more than 9,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN:  DE000A1K0227). Executive Board: Dirk Hessel (CEO) and Vilma Methner (COO, CSO). More information can be found at  and


Press Contact

Matthias Meißner
Tel. +49 (0)3328-43460
Fax +49 (0)3328-434643